Review





Similar Products

99
ATCC human 786 o clear cell renal cell carcinoma cells
Compound 100 induces ferroptosis and engages GPX4 in cancer cells. (A) Relative viability of human cancer cell lines (ES-2, <t>786-O,</t> 769-P, OVCAR-8, Daudi, and SU-DHL-4) and mouse cancer cell lines (LLC1 and MC-38) treated with KY0100, ML210, or RSL3 in the presence or absence of Lip-1. (B) Representative BODIPY-C11 fluorescence images of ES-2 cells treated with DMSO or increasing concentrations of compound 100 (0.5–5 µM), with or without Lip-1. Reduced and oxidized BODIPY-C11 signals are shown separately and as merged images. Scale bars, 50 µm. (C) Chemical structures of compound 100-yne and the control alkyne and schematic workflow for cellular labeling, CuAAC conjugation, affinity enrichment, in-gel fluorescence, and immunoblot analysis. (D) Relative viability of LLC1 cells treated with KY0100 or KY0100-yne in the presence or absence of Lip-1. (E) In-gel fluorescence of LLC1 cells treated with DMSO, control alkyne, or compound 100-yne. (F) GPX4 immunoblot analysis of input, unbound, and affinity-enriched fractions following compound 100-yne labeling of LLC1 cells.
Human 786 O Clear Cell Renal Cell Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/786-O/pmc13758398-285-0-7
Average 99 stars, based on 1 article reviews
human 786 o clear cell renal cell carcinoma cells - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

97
New England Biolabs o glycosidase
Compound 100 induces ferroptosis and engages GPX4 in cancer cells. (A) Relative viability of human cancer cell lines (ES-2, <t>786-O,</t> 769-P, OVCAR-8, Daudi, and SU-DHL-4) and mouse cancer cell lines (LLC1 and MC-38) treated with KY0100, ML210, or RSL3 in the presence or absence of Lip-1. (B) Representative BODIPY-C11 fluorescence images of ES-2 cells treated with DMSO or increasing concentrations of compound 100 (0.5–5 µM), with or without Lip-1. Reduced and oxidized BODIPY-C11 signals are shown separately and as merged images. Scale bars, 50 µm. (C) Chemical structures of compound 100-yne and the control alkyne and schematic workflow for cellular labeling, CuAAC conjugation, affinity enrichment, in-gel fluorescence, and immunoblot analysis. (D) Relative viability of LLC1 cells treated with KY0100 or KY0100-yne in the presence or absence of Lip-1. (E) In-gel fluorescence of LLC1 cells treated with DMSO, control alkyne, or compound 100-yne. (F) GPX4 immunoblot analysis of input, unbound, and affinity-enriched fractions following compound 100-yne labeling of LLC1 cells.
O Glycosidase, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/O-Glycosidase/pmc13754027-443-29-35
Average 97 stars, based on 1 article reviews
o glycosidase - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

786 o  (ATCC)
99
ATCC 786 o
Compound 100 induces ferroptosis and engages GPX4 in cancer cells. (A) Relative viability of human cancer cell lines (ES-2, <t>786-O,</t> 769-P, OVCAR-8, Daudi, and SU-DHL-4) and mouse cancer cell lines (LLC1 and MC-38) treated with KY0100, ML210, or RSL3 in the presence or absence of Lip-1. (B) Representative BODIPY-C11 fluorescence images of ES-2 cells treated with DMSO or increasing concentrations of compound 100 (0.5–5 µM), with or without Lip-1. Reduced and oxidized BODIPY-C11 signals are shown separately and as merged images. Scale bars, 50 µm. (C) Chemical structures of compound 100-yne and the control alkyne and schematic workflow for cellular labeling, CuAAC conjugation, affinity enrichment, in-gel fluorescence, and immunoblot analysis. (D) Relative viability of LLC1 cells treated with KY0100 or KY0100-yne in the presence or absence of Lip-1. (E) In-gel fluorescence of LLC1 cells treated with DMSO, control alkyne, or compound 100-yne. (F) GPX4 immunoblot analysis of input, unbound, and affinity-enriched fractions following compound 100-yne labeling of LLC1 cells.
786 O, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/786-O/pmc13754096-121-1-11
Average 99 stars, based on 1 article reviews
786 o - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

94
Emulseo fluosurf surfactant
Compound 100 induces ferroptosis and engages GPX4 in cancer cells. (A) Relative viability of human cancer cell lines (ES-2, <t>786-O,</t> 769-P, OVCAR-8, Daudi, and SU-DHL-4) and mouse cancer cell lines (LLC1 and MC-38) treated with KY0100, ML210, or RSL3 in the presence or absence of Lip-1. (B) Representative BODIPY-C11 fluorescence images of ES-2 cells treated with DMSO or increasing concentrations of compound 100 (0.5–5 µM), with or without Lip-1. Reduced and oxidized BODIPY-C11 signals are shown separately and as merged images. Scale bars, 50 µm. (C) Chemical structures of compound 100-yne and the control alkyne and schematic workflow for cellular labeling, CuAAC conjugation, affinity enrichment, in-gel fluorescence, and immunoblot analysis. (D) Relative viability of LLC1 cells treated with KY0100 or KY0100-yne in the presence or absence of Lip-1. (E) In-gel fluorescence of LLC1 cells treated with DMSO, control alkyne, or compound 100-yne. (F) GPX4 immunoblot analysis of input, unbound, and affinity-enriched fractions following compound 100-yne labeling of LLC1 cells.
Fluosurf Surfactant, supplied by Emulseo, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/FluoSurf+Nonionic+Surfactant/pm43010417-84-31-33
Average 94 stars, based on 1 article reviews
fluosurf surfactant - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

99
Beyotime safranin o
(A) H&E staining, safranin O-fast green staining and alcian blue staining. (B) Mankin score for evaluating the degree of condylar cartilage damage after modeling. ** P < 0.01, *** P < 0.005, **** P < 0.0001.(C) H&E staining and Masson staining. (D) OARSI score statistics. ** P < 0.01, *** P < 0.005, **** P < 0.0001. OA, osteoarthritis; TMJOA, temporomandibular joint OA; OARSI, OA research society international.
Safranin O, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/Safranine+O+and+Fast+Green+Cartilage+Staining+Kit/pmc13750604-40-10-15
Average 99 stars, based on 1 article reviews
safranin o - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

95
Chem Impex International bis dimethylamino methylene
(A) H&E staining, safranin O-fast green staining and alcian blue staining. (B) Mankin score for evaluating the degree of condylar cartilage damage after modeling. ** P < 0.01, *** P < 0.005, **** P < 0.0001.(C) H&E staining and Masson staining. (D) OARSI score statistics. ** P < 0.01, *** P < 0.005, **** P < 0.0001. OA, osteoarthritis; TMJOA, temporomandibular joint OA; OARSI, OA research society international.
Bis Dimethylamino Methylene, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/O-(7-Azabenzotriazol-1-yl)-N%2CN%2CN'%2CN'-tetramethyluronium+hexafluorophosphate/pmc13746262-119-0-10
Average 95 stars, based on 1 article reviews
bis dimethylamino methylene - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

99
Gilead Sciences c 22 h 29 fn 3 o 9 p cid 45375808
Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.
C 22 H 29 Fn 3 O 9 P Cid 45375808, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/Epclusa/pmc13748950-5-18-40
Average 99 stars, based on 1 article reviews
c 22 h 29 fn 3 o 9 p cid 45375808 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

97
New England Biolabs t4 rna ligation buffer w o dtt

T4 Rna Ligation Buffer W O Dtt, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/T4+RNA+Ligase+Reaction+Buffer/pmc13769472-548-36-42
Average 97 stars, based on 1 article reviews
t4 rna ligation buffer w o dtt - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

99
Beyotime modified oil red o staining kit

Modified Oil Red O Staining Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/o%26m+tool/Modified+Oil+Red+O+Staining+Kit/pm42994998-84-7-13
Average 99 stars, based on 1 article reviews
modified oil red o staining kit - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


Compound 100 induces ferroptosis and engages GPX4 in cancer cells. (A) Relative viability of human cancer cell lines (ES-2, 786-O, 769-P, OVCAR-8, Daudi, and SU-DHL-4) and mouse cancer cell lines (LLC1 and MC-38) treated with KY0100, ML210, or RSL3 in the presence or absence of Lip-1. (B) Representative BODIPY-C11 fluorescence images of ES-2 cells treated with DMSO or increasing concentrations of compound 100 (0.5–5 µM), with or without Lip-1. Reduced and oxidized BODIPY-C11 signals are shown separately and as merged images. Scale bars, 50 µm. (C) Chemical structures of compound 100-yne and the control alkyne and schematic workflow for cellular labeling, CuAAC conjugation, affinity enrichment, in-gel fluorescence, and immunoblot analysis. (D) Relative viability of LLC1 cells treated with KY0100 or KY0100-yne in the presence or absence of Lip-1. (E) In-gel fluorescence of LLC1 cells treated with DMSO, control alkyne, or compound 100-yne. (F) GPX4 immunoblot analysis of input, unbound, and affinity-enriched fractions following compound 100-yne labeling of LLC1 cells.

Journal: RSC Chemical Biology

Article Title: Development of isourea-based covalent GPX4 inhibitors and structure–activity relationship analysis in ferroptosis induction

doi: 10.1039/d6cb00321d

Figure Lengend Snippet: Compound 100 induces ferroptosis and engages GPX4 in cancer cells. (A) Relative viability of human cancer cell lines (ES-2, 786-O, 769-P, OVCAR-8, Daudi, and SU-DHL-4) and mouse cancer cell lines (LLC1 and MC-38) treated with KY0100, ML210, or RSL3 in the presence or absence of Lip-1. (B) Representative BODIPY-C11 fluorescence images of ES-2 cells treated with DMSO or increasing concentrations of compound 100 (0.5–5 µM), with or without Lip-1. Reduced and oxidized BODIPY-C11 signals are shown separately and as merged images. Scale bars, 50 µm. (C) Chemical structures of compound 100-yne and the control alkyne and schematic workflow for cellular labeling, CuAAC conjugation, affinity enrichment, in-gel fluorescence, and immunoblot analysis. (D) Relative viability of LLC1 cells treated with KY0100 or KY0100-yne in the presence or absence of Lip-1. (E) In-gel fluorescence of LLC1 cells treated with DMSO, control alkyne, or compound 100-yne. (F) GPX4 immunoblot analysis of input, unbound, and affinity-enriched fractions following compound 100-yne labeling of LLC1 cells.

Article Snippet: Human 786-O clear-cell renal cell carcinoma cells (ATCC, CRL-1932), ES-2 ovarian clear-cell carcinoma cells (ATCC, CRL-1978), 769-P renal carcinoma cells (ATCC, CRL-1933), and MDA-MB-468 breast carcinoma cells (ATCC, HTB-132) were obtained from the American Type Culture Collection (ATCC).

Techniques: Fluorescence, Control, Labeling, Conjugation Assay, Western Blot, Analysis

Pharmacokinetic properties of compounds 268 and 220 in mice

Journal: RSC Chemical Biology

Article Title: Development of isourea-based covalent GPX4 inhibitors and structure–activity relationship analysis in ferroptosis induction

doi: 10.1039/d6cb00321d

Figure Lengend Snippet: Pharmacokinetic properties of compounds 268 and 220 in mice

Article Snippet: Human 786-O clear-cell renal cell carcinoma cells (ATCC, CRL-1932), ES-2 ovarian clear-cell carcinoma cells (ATCC, CRL-1978), 769-P renal carcinoma cells (ATCC, CRL-1933), and MDA-MB-468 breast carcinoma cells (ATCC, HTB-132) were obtained from the American Type Culture Collection (ATCC).

Techniques:

Ferroptosis responsiveness of MDA-MB-468 cells and antitumor activity of compound 380 in MDA-MB-468 and 786-O xenograft models. (A) Relative viability of MDA-MB-468 cells treated with compound 418, ML162, or a GPX4 degrader N6F11 in the presence or absence of Lip-1. (B) Tumor growth of MDA-MB-468 and 786-O xenografts in CB17 SCID mice treated orally with compound 380 ( n = 5 mice per group). MDA-MB-468 tumor-bearing mice received 380 at 3.0 or 7.5 mg kg −1 twice daily (BID) for up to 35 days. In the 786-O xenograft model, mice received 3.0 mg kg −1 BID throughout the study, whereas the 7.5 mg kg −1 group received BID dosing through day 9 followed by once-daily (QD) dosing through day 17.

Journal: RSC Chemical Biology

Article Title: Development of isourea-based covalent GPX4 inhibitors and structure–activity relationship analysis in ferroptosis induction

doi: 10.1039/d6cb00321d

Figure Lengend Snippet: Ferroptosis responsiveness of MDA-MB-468 cells and antitumor activity of compound 380 in MDA-MB-468 and 786-O xenograft models. (A) Relative viability of MDA-MB-468 cells treated with compound 418, ML162, or a GPX4 degrader N6F11 in the presence or absence of Lip-1. (B) Tumor growth of MDA-MB-468 and 786-O xenografts in CB17 SCID mice treated orally with compound 380 ( n = 5 mice per group). MDA-MB-468 tumor-bearing mice received 380 at 3.0 or 7.5 mg kg −1 twice daily (BID) for up to 35 days. In the 786-O xenograft model, mice received 3.0 mg kg −1 BID throughout the study, whereas the 7.5 mg kg −1 group received BID dosing through day 9 followed by once-daily (QD) dosing through day 17.

Article Snippet: Human 786-O clear-cell renal cell carcinoma cells (ATCC, CRL-1932), ES-2 ovarian clear-cell carcinoma cells (ATCC, CRL-1978), 769-P renal carcinoma cells (ATCC, CRL-1933), and MDA-MB-468 breast carcinoma cells (ATCC, HTB-132) were obtained from the American Type Culture Collection (ATCC).

Techniques: Activity Assay, Xenograft Assay

(A) H&E staining, safranin O-fast green staining and alcian blue staining. (B) Mankin score for evaluating the degree of condylar cartilage damage after modeling. ** P < 0.01, *** P < 0.005, **** P < 0.0001.(C) H&E staining and Masson staining. (D) OARSI score statistics. ** P < 0.01, *** P < 0.005, **** P < 0.0001. OA, osteoarthritis; TMJOA, temporomandibular joint OA; OARSI, OA research society international.

Journal: PLOS One

Article Title: HIF-1α expression is associated to cell proliferation and ECM production in temporomandibular joint osteoarthritis

doi: 10.1371/journal.pone.0361577

Figure Lengend Snippet: (A) H&E staining, safranin O-fast green staining and alcian blue staining. (B) Mankin score for evaluating the degree of condylar cartilage damage after modeling. ** P < 0.01, *** P < 0.005, **** P < 0.0001.(C) H&E staining and Masson staining. (D) OARSI score statistics. ** P < 0.01, *** P < 0.005, **** P < 0.0001. OA, osteoarthritis; TMJOA, temporomandibular joint OA; OARSI, OA research society international.

Article Snippet: After dewaxing and gradient hydration, standard hematoxylin and eosin (H&E), safranin O and fast green (Beyotime Institute of Biotechnology) and alcian blue staining (C0155S, Beyotime Institute of Biotechnology) was used to assess the health status of cartilage and evaluate the effectiveness of cartilage repair.

Techniques: Staining, Safranin O Staining, Alcian Blue Staining, Masson's Trichrome Staining

(A) Morphology of MCCs under light microscopy, immunofluorescence of COLII, SOX9, and Toluidine blue, alcian blue and Safranin O staining of MCCs. Scale bar, 200 μm; Scale bar, 100 μm. (B) Schematic diagram of hypoxia device. (C) EdU was used to detect the changes in the proliferation rate of MCCs under hypoxic conditions. (D) Quantitative statistics of EdU levels in hypoxia at different time-points, * P < 0.05, *** P < 0.001, **** P < 0.0001. n = 3. (E) The protein and semi-quantitative statistical chart of PCNA in hypoxia at different time-points, * P < 0.05. n = 3. (F) Immunofluorescence of HIF-1α in hypoxia; Scale bar, 50μm. (G) Immunofluorescence positive analysis of HIF-1α, **** P < 0.0001. n = 3. (H) The protein and semi-quantitative statistical diagram of HIF-1α in hypoxic chamber. * P < 0.05, *** P < 0.001, **** P < 0.0001. n = 3. ns, not statistically significant; TMJOA, temporomandibular joint osteoarthritis; HIF-1α, hypoxia-inducible factor 1α; PCNA, proliferating cell nuclear antigen; MCCs, mandibular condylar chondrocytes.

Journal: PLOS One

Article Title: HIF-1α expression is associated to cell proliferation and ECM production in temporomandibular joint osteoarthritis

doi: 10.1371/journal.pone.0361577

Figure Lengend Snippet: (A) Morphology of MCCs under light microscopy, immunofluorescence of COLII, SOX9, and Toluidine blue, alcian blue and Safranin O staining of MCCs. Scale bar, 200 μm; Scale bar, 100 μm. (B) Schematic diagram of hypoxia device. (C) EdU was used to detect the changes in the proliferation rate of MCCs under hypoxic conditions. (D) Quantitative statistics of EdU levels in hypoxia at different time-points, * P < 0.05, *** P < 0.001, **** P < 0.0001. n = 3. (E) The protein and semi-quantitative statistical chart of PCNA in hypoxia at different time-points, * P < 0.05. n = 3. (F) Immunofluorescence of HIF-1α in hypoxia; Scale bar, 50μm. (G) Immunofluorescence positive analysis of HIF-1α, **** P < 0.0001. n = 3. (H) The protein and semi-quantitative statistical diagram of HIF-1α in hypoxic chamber. * P < 0.05, *** P < 0.001, **** P < 0.0001. n = 3. ns, not statistically significant; TMJOA, temporomandibular joint osteoarthritis; HIF-1α, hypoxia-inducible factor 1α; PCNA, proliferating cell nuclear antigen; MCCs, mandibular condylar chondrocytes.

Article Snippet: After dewaxing and gradient hydration, standard hematoxylin and eosin (H&E), safranin O and fast green (Beyotime Institute of Biotechnology) and alcian blue staining (C0155S, Beyotime Institute of Biotechnology) was used to assess the health status of cartilage and evaluate the effectiveness of cartilage repair.

Techniques: Morphology, Light Microscopy, Immunofluorescence, Safranin O Staining, Analysis

Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.

Journal: MedComm

Article Title: Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects

doi: 10.1002/mco2.71024

Figure Lengend Snippet: Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.

Article Snippet: Sofosbuvir Nucleotide prodrug; HCV NS5B polymerase inhibitor; chronic HCV; US FDA‐approved alone and in fixed‐dose DAA combinations , C 22 H 29 FN 3 O 9 P; CID 45375808 , Velpatasvir HCV NS5A inhibitor; chronic HCV; US FDA‐approved with sofosbuvir (Epclusa) and in sofosbuvir/velpatasvir/voxilaprevir (Vosevi) , C 49 H 54 N 8 O 8 ; CID 67683363.

Techniques: Reverse Transcription, Mutagenesis, Inhibition, Protease Inhibitor, Analogues, Membrane

Journal: iScience

Article Title: RNA-binding proteome dynamics following ischemia-reperfusion injury in the kidney

doi: 10.1016/j.isci.2026.118143

Figure Lengend Snippet:

Article Snippet: After that, the biotin-labeling was performed using biotinylated cytidine (bis)phosphate (pCp-Biotin) with T4 RNA Ligase Reaction mixture (18,7 nM pCp-Biotin (Jena Bioscience, NU-1706-BIO), 1 mM ATP (NEB, P0756S), 3.5% (v/v) DMSO, 0.025% (v/v) Tween 20, 1× T4 RNA Ligation Buffer w/o DTT (NEB, B0216S), 20% PEG8000 (NEB, B1004S), 20U Murine RNase Inhibitor (NEB, M0314L) and 30U T4 RNA Ligase 1 (NEB, M0437M)).

Techniques: